Abcuro, Inc Secures $200M Series C to Propel First-in-Class Anti-KLRG1 Therapies for Autoimmune and Cancer Indications

Abcuro, Inc, a pioneering clinical stage biotechnology company, is excited to announce a significant milestone in its journey with a funding raise of $200,000,000. This capital injection will be strategically allocated to accelerate the development of the company’s innovative treatments targeting autoimmune disorders and cancer indications. Abcuro focuses on modulating cytotoxic T and natural killer (NK) cells that express the inhibitory immune checkpoint receptor KLRG1—a critical player in immune regulation. The company’s lead candidate, ABC008, is a first-in-class anti-KLRG1 antibody that aims to address the unmet medical need in inclusion body myositis (IBM). IBM is a progressive and debilitating inflammatory condition of skeletal muscle, for which there are currently no approved pharmaceutical therapies. The recent FDA orphan drug designation for ABC008 in IBM further underscores the transformative potential of this therapy and highlights the regulatory commitment to bring a novel treatment option to patients in dire need. In addition to advancing ABC008 into clinical studies, the funding will also support the development of ABC015, an anti-KLRG1 blocking antibody designed to reactivate inhibited cytotoxic T and NK cells within the tumor microenvironment. This dual-pronged approach not only exemplifies Abcuro’s commitment to addressing serious health conditions through innovative science-driven solutions but also represents a significant step towards improving patient outcomes in both autoimmune diseases and cancer. The new funding will enable the company to expand its clinical trial programs, enhance manufacturing capabilities, and deepen research initiatives, positioning Abcuro at the forefront of cutting-edge immunotherapy and offering renewed hope and potential relief for patients worldwide.